gefitinib has been researched along with sf 1126 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (sf 1126) | Trials (sf 1126) | Recent Studies (post-2010) (sf 1126) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 15 | 2 | 13 |
| Protein | Taxonomy | gefitinib (IC50) | sf 1126 (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, M; Liu, D; Wang, J; Zhang, L | 1 |
1 other study(ies) available for gefitinib and sf 1126
| Article | Year |
|---|---|
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Drug Interactions; ErbB Receptors; Female; Gefitinib; Humans; Oligopeptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2015 |